<SEC-DOCUMENT>0001193125-18-029526.txt : 20180202
<SEC-HEADER>0001193125-18-029526.hdr.sgml : 20180202
<ACCEPTANCE-DATETIME>20180201174406
ACCESSION NUMBER:		0001193125-18-029526
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180201
FILED AS OF DATE:		20180202
DATE AS OF CHANGE:		20180201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		18567906

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d532897d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated February 1, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9746;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February 1, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d532897dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g532897g67d72.gif" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1&nbsp;February 2018 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>IMMUTEP LIMITED ANNOUNCES
MILESTONE PAYMENT FROM </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>CHINESE PARTNER EOC PHARMA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA &#150; Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced today that it has received a milestone payment from the Company&#146;s Chinese
partner for eftilagimod alpha (IMP321), EOC Pharma, an oncology focused affiliate of Eddingpharm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The milestone payment of US$1 million relates to the
clinical development of eftilagimod alpha in China and follows the granting of EOC Pharma&#146;s Investigational New Drug (IND) application in China, as outlined in Immutep&#146;s December&nbsp;12, 2017 <U>Operational Update</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt, commented, &#147;We are very pleased with the recent progress EOC Pharma has made in China. Given the recent regulatory reform, we
are optimistic about eftilagimod&#146;s navigation of the Chinese Food and Drug Administration&#146;s regulatory pathway and its clinical development. We look forward to supporting our partner EOC Pharma.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EOC&#146;s CEO Xiaoming Zou, added, &#147;We have been encouraged by the CFDA approval of the IND. Eftilagimod alpha showed impressive activity in a European
Phase 1 clinical trial as well as in the safety run in phase of AIPAC in metastatic breast cancer, and we are confident Chinese patients will experience similar clinical benefit. We also look forward to entering a new phase of collaboration with our
partner Immutep.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2013, Immutep and Eddingpharm entered into a licensing agreement whereby Immutep granted Eddingpharm exclusive development
rights for eftilagimod in China, including Hong Kong, Macau, and Taiwan. In January 2015, the license was transferred from Eddingpharm to EOC Pharma upon the consent of Immutep. In exchange for these rights, EOC Pharma agreed to pay for the
manufacturing of certain drug supply for Immutep and will be required to make milestone payments to Immutep if eftilagimod achieves specified development milestones. EOC Pharma will also pay Immutep a royalty on net sales of eftilagimod in China, if
approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About EOC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EOC is a fast-growing,
Shanghai-based biopharmaceutical company that is focused on the in-licensing of innovative global oncology products, and developing, manufacturing and commercializing them for the China market. EOC is building a fully integrated manufacturing,
development and commercialization platform, and has a pipeline of six novel products from global biopharmaceutical partners that are potentially first- and best-in-class. EOC is a spin-off of the oncology division of Eddingpharm, a leading specialty
pharmaceutical company in China that dedicates to in-licensing, marketing and commercializing branded drugs from global pharmaceutical companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep (formerly named Prima BioMed Ltd)
is a globally active biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g532897g67d72.gif" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company is the global leader in the understanding and development of therapies that modulate Lymphocyte Activation Gene-3 (&#147;LAG-3&#148;), a cell surface molecule which plays a vital role in
regulating T cells and was discovered by the Company&#146;s Chief Scientific and Medical Officer, Dr.&nbsp;Frederic Triebel. Immutep&#146;s objective is to harness and strengthen the power of patients&#146; immune systems through therapeutic
intervention for the benefit of patients&#146; health. Immutep&#146;s current lead product is eftilagimod alpha, a first-in-class soluble LAG-3Ig fusion protein that is also an antigen presenting cell (&#147;APC&#148;) activator currently being
investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma. A number of additional LAG-3 products, including antibodies for immune response modulation in autoimmunity and cancer
are being developed by large pharmaceutical partners. Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the U.S. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>U.S.
Investors: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Vice President of Business Development and Investor Relations, Immutep </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917)&nbsp;860-9404; <U>jay.campbell@immutep.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew
Beck, The Trout Group LLC +1 (646)&nbsp;378-2933; <U>mbeck@troutgroup.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Australian Investors/Media: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel-MAGNUS +61 (2)&nbsp;8234 0100; <U> </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mgregorowski@citadelmagnus.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g532897g67d72.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532897g67d72.gif
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MG*W6K:7.M;W>O0
M
M
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MTY-@ABGF(E$2"&0S/Y"P @&_C>GFF\_\L ():K99P <KY, # #;8@((,&+P
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M*@=$FNA<#[U"!)= "'3^ 8U MBIM!0$),(@!%C 0[%%? #^*.0&F7( !6F6
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D^9O &9S".9S$69S&>9S(F9S*N9S,V9S.^9S0&9W2V9N!   [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
